PharVision Advisers’s GCM Grosvenor GCMG Stock Holding History

PharVision Advisers’s Portfolio GCMG Stock Details GCMG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-44,256	Closed	-$501K	–	318
2025 Q4	$501K	Buy	44,256 +8,071	+22%	+$92.2K	0.25%	43
2025 Q3	$437K	Buy	+36,185	New	+$449K	0.25%	48

Other funds holding GCMG

Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

PharVision Advisers's GCMG Position: Q1 2026 in Review

PharVision Advisers sold out of GCM Grosvenor (GCMG) in Q1 2026, closing a stake of 44,256 shares — an estimated $501K sold.

PharVision Advisers first reported a position in GCMG in Q3 2025 and held it in 2 quarters. The position peaked at $501K in Q4 2025. 147 funds tracked by Wall St. Rank hold GCMG as of Q1 2026.

PharVision Advisers reported no remaining GCM Grosvenor position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 44,256 GCM Grosvenor shares in Q1 2026, an estimated $501K.
PharVision Advisers first reported a position in GCM Grosvenor in Q3 2025 and held it in 2 quarters.
PharVision Advisers's GCM Grosvenor position peaked at $501K in Q4 2025.
147 funds tracked by Wall St. Rank held GCM Grosvenor as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.